Santhera Pharmaceuticals Holding AG (SANN) - Total Liabilities
Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SANN) has total liabilities worth CHF159.90 Million CHF (≈ $202.16 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Santhera Pharmaceuticals Holding AG to see how much of total assets are deployed in long-term investments.
Santhera Pharmaceuticals Holding AG - Total Liabilities Trend (2006–2025)
This chart illustrates how Santhera Pharmaceuticals Holding AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Santhera Pharmaceuticals Holding AG balance sheet assets.
Santhera Pharmaceuticals Holding AG Competitors by Total Liabilities
The table below lists competitors of Santhera Pharmaceuticals Holding AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
E. W. Scripps Co Class A
NASDAQ:SSP
|
USA | $3.55 Billion |
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM
|
USA | $6.38 Million |
|
Stille AB
ST:STIL
|
Sweden | Skr362.30 Million |
|
Chen Full International Co Ltd
TWO:8383
|
Taiwan | NT$2.25 Billion |
|
Jena Acquisition Corporation II
NYSE:JENA
|
USA | $14.61 Million |
|
Amazing Microelectronic
TWO:6411
|
Taiwan | NT$1.67 Billion |
|
Cohen & Steers Real Estate Opportunities and Income Fund
NYSE:RLTY
|
USA | $143.70 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Santhera Pharmaceuticals Holding AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Santhera Pharmaceuticals Holding AG to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -13.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Santhera Pharmaceuticals Holding AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Santhera Pharmaceuticals Holding AG (2006–2025)
The table below shows the annual total liabilities of Santhera Pharmaceuticals Holding AG from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF159.90 Million ≈ $202.16 Million |
+28.14% |
| 2024-12-31 | CHF124.79 Million ≈ $157.77 Million |
+151.16% |
| 2023-12-31 | CHF49.69 Million ≈ $62.82 Million |
-53.74% |
| 2022-12-31 | CHF107.41 Million ≈ $135.80 Million |
+19.63% |
| 2021-12-31 | CHF89.79 Million ≈ $113.52 Million |
-5.53% |
| 2020-12-31 | CHF95.04 Million ≈ $120.16 Million |
+1.32% |
| 2019-12-31 | CHF93.80 Million ≈ $118.59 Million |
+13.75% |
| 2018-12-31 | CHF82.47 Million ≈ $104.26 Million |
+6.37% |
| 2017-12-31 | CHF77.52 Million ≈ $98.01 Million |
+371.53% |
| 2016-12-31 | CHF16.44 Million ≈ $20.79 Million |
+50.77% |
| 2015-12-31 | CHF10.90 Million ≈ $13.79 Million |
+91.08% |
| 2014-12-31 | CHF5.71 Million ≈ $7.22 Million |
+117.00% |
| 2013-12-31 | CHF2.63 Million ≈ $3.33 Million |
-59.88% |
| 2012-12-31 | CHF6.55 Million ≈ $8.29 Million |
-27.57% |
| 2011-12-31 | CHF9.05 Million ≈ $11.44 Million |
-0.97% |
| 2010-12-31 | CHF9.14 Million ≈ $11.55 Million |
-18.32% |
| 2009-12-31 | CHF11.19 Million ≈ $14.15 Million |
+32.05% |
| 2008-12-31 | CHF8.47 Million ≈ $10.71 Million |
-2.17% |
| 2007-12-31 | CHF8.66 Million ≈ $10.95 Million |
-16.29% |
| 2006-12-31 | CHF10.35 Million ≈ $13.08 Million |
-- |
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more